EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial

John Bradley iD, Emmanuel Roilides, Margaret Tawadrous, Jean Li Yan, Elena Soto, Gregory G Stone, Shweta Kamat, Paurus Irani, Richard England

Journal of the Pediatric Infectious Diseases Society · 13.05.2025 · 14 (5)

DOI: 10.1093/jpids/piaf028 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, online erschienen am 19.04.2025. Verfasst von John Bradley und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Rady Children's Hospital, University of California San Diego School of Medicine, San Diego, CA, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Ceftazidime, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This phase 2a study evaluated pharmacokinetics and safety of ceftazidime-avibactam (CAZ/AVI; combination dosed as fixed 4:1 ratio) in neonates and young infants with suspected/confirmed infections due to Gram-negative pathogens requiring intravenous antibiotics.

Methods

Hospitalized neonates and infants (gestational age ≥ 26 weeks to < 3 months), enrolled sequentially into 3 age cohorts, received CAZ/AVI single dose (Part A) or multiple dose every 8 h (Part B) by 2-h intravenous infusions. Infants > 28 days (Cohort 1) received CAZ/AVI 37.5 mg/kg/dose (CAZ 30 mg/kg and AVI 7.5 mg/kg). Full-term neonates ≤ 28 days (Cohort 2) and preterm neonates ≤ 28 days (Cohort 3) received 25 mg/kg/dose (CAZ 20 mg/kg and AVI 5 mg/kg). Pharmacokinetics, safety, and clinical and microbiological outcomes (Part B only) were assessed descriptively.

Results

Forty-six patients received CAZ/AVI, 25 in Part A and 21 in Part B. Sepsis (39.1%) and urinary tract infection (15.2%) were the predominant diagnoses. Observed drug plasma-concentration time profiles were generally similar across cohorts. Overall, 23 patients (50%) had ≥ 1 adverse event (AE), 8 patients (17.4%) had ≥ 1 serious AE (SAE), and 2 patients (4.3%) died; no SAE or death was treatment related. In Part B, ≥ 80% of patients had favorable clinical and microbiological responses.

Conclusions

Plasma exposures after single and multiple CAZ/AVI doses in neonates and young infants < 3 months old (37.5 [30/7.5] mg/kg/dose for > 28 days; 25 [20/5] mg/kg/dose for ≤ 28 days) were similar to approved doses for older children. The safety profile of CAZ/AVI was as expected based on previous observations. Study funded by Pfizer.

Trial registration

NCT04126031.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeGram-Negative Bacterial InfectionsFemaleHumansInfantInfant, NewbornMaleDrug CombinationsInfusions, IntravenousProspective Studies

Stichwörter der Autor:innen

Gram-negative bacteriaantibiotic therapyantimicrobial resistanceneonatal infectionsepsis

Substanzen

Anti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeDrug Combinations

Autor:innen und Institutionen

  • Department of Pediatrics, Rady Children's Hospital, University of California San Diego School of Medicine, San Diego, CA, USA.
  • 3rd Department of Pediatrics, Aristotle University and Hippokration Hospital, Thessaloniki, Greece.
  • Research and Development, Pfizer Inc., Groton, CT, USA.
  • Research and Development, Pfizer Inc., Cambridge, MA, USA.
  • Pharmacometrics and Systems Pharmacology, Pfizer Research and Development, Pfizer Inc., Sandwich, Kent, UK.
  • Global Medical Affairs, Pfizer India Ltd., Mumbai, India.

ORCID-Profile: John Bradley

Förderung

  • Pfizer
  • AbbVie

Zitieren

APA

Bradley, J., Roilides, E., Tawadrous, M., Yan, J. L., Soto, E., Stone, G. G., Kamat, S., Irani, P., & England, R. (2025). Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial. Journal of the Pediatric Infectious Diseases Society, 14(5). https://doi.org/10.1093/jpids/piaf028

Vancouver

Bradley J, Roilides E, Tawadrous M, Yan JL, Soto E, Stone GG, et al. Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial. Journal of the Pediatric Infectious Diseases Society. 2025;14(5). doi:10.1093/jpids/piaf028

BibTeX
@article{Bradley2025,
  author = {Bradley, John and Roilides, Emmanuel and Tawadrous, Margaret and Yan, Jean Li and Soto, Elena and Stone, Gregory G and Kamat, Shweta and Irani, Paurus and England, Richard},
  title = {Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2025},
  volume = {14},
  number = {5},
  doi = {10.1093/jpids/piaf028}
}
Kostenlos starten →